Report
Karen Andersen
EUR 100.00 For Business Accounts Only

Myriad's Genetic Testing Suite Upholds Its Narrow Moat

Narrow-moat Myriad Genetics reported over $216 million in revenue for the second quarter of fiscal-year 2019, up 15% from last year, in line with previous guidance and mostly in line with our expectations. Although the GAAP earnings of $0.03 per share missed management's guidance by a penny, adjusted earnings were in line with guidance and our expectations. Both revenue and earnings missed consensus expectations slightly. After reports of continued hiccups with GeneSight, we're lowering our reve...
Underlying
Myriad Genetics Inc.

Myriad Genetics is a precision medicine company acting as a trusted advisor to transform patient lives through molecular diagnostics. The company's molecular diagnostic tests include: myRisk? Hereditary Cancer for assessing the risks for hereditary cancers; BRACAnalysis? for assessing the risk of developing breast and ovarian cancer; riskScore? that improves the company's myRisk Hereditary Cancer test; GeneSight? to support psychotropic drug selection for depressed patients; Vectra?DA for assessing the disease activity of rheumatoid arthritis; and Prolaris? for assessing the aggressiveness of prostate cancer. The company also provides pharmaceutical and clinical services.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Karen Andersen

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch